



Press
release

Montpellier, France, November 04th 2020 – 6.00pm

Myrian 2.8 launch, new clinical applications and workflow efficiency

Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions and Myrian® designer, is pleased to present the new version 2.8 of its visualization platform with many new features, from clinical applications to improved workflow.

Clinical innovations and enhanced user experience

The most common cancer in women, breast cancer is a pathology that Intrasense has been involved in for many years. The XP-Mammo application now includes tomosynthesis in version 2.8. This new very powerful tool allows the reading of standard mammographic images, tomosynthesis, as well as the comparison with previous examinations. In addition, and without changing the interface, it is also possible via this platform dedicated to mammography, to view additional ultrasound examinations and MRI sequences. This greatly improves the comfort of reading and analysis of the radiologist to optimize diagnosis for patient. XP-Mammo is now the most complete mammography solution on the market and enriches the clinical applications catalog dedicated to senology alongside XP-Breast for MRI exams.

Myrian XP-Cardiac integrates many new features in a single application, such as the automatic calculation of the calcium scoring (Agagston score) but also the multiphase reading in order to visualize different acquisitions based on the ECG (electrocardiogram). The workflow has been reworked has been reworked to be simpler and allow faster exam analysis: now labels and views are synchronized and specific steps for stenosis analysis and stent planning have been added. Finally, reporting has been improved with a stenosis classification.

Intrasense has also developed a new cerebral perfusion application: Myrian XP-BrainPerfusion-CT which allows stroke analyzes to be performed and a mismatch automatic calculation. The certification of this application is in progress in Europe and United States.

During the first wave of the COVID-19 pandemic, the company also launched a new scanner reading protocol specifically dedicated to the quantification and analysis of pulmonary lesions from Coronavirus. CE certified and FDA approved, it is now integrated into the Myrian XP-Lung segmentation application in version 2.8.



These new features allow Intrasense to strengthen its positioning in its main markets, Europe and China.

About Intrasense

Founded in 2004, Intrasense develops and markets a unique medical device named Myrian®, a software platform facilitating and ensuring diagnosis, decision-making and therapeutic follow-up. Thanks to Myrian®, more than 1000 hospitals and clinics spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner...). Enriched with expert clinical modules dedicated to specific pathologies and organs, Myrian® provides a universal medical image processing solution which can be fully integrated into any healthcare information system. Intrasense has more than 40 employees among which 15 are dedicated to Research & Development. Intrasense has been labelled 'innovative company' by the BPI and has invested more than 10 million euros in Research & Development since its creation. More information on: www.intrasense.fr

Contacts

Intrasense
Jérémy Peyron
Marketing & Communication manager
1231 avenue du Mondial 98, 34000
Montpellier, FRANCE
Tel: +334 67 130 130
investor@intrasense.fr

NewCap
Investor Relations and Financial
Communication
Roxane Gbedigro
Paris, FRANCE
Tel: +331 44 71 20 43
intrasense@newcap.eu

